FDA grants clearance for CardioDynamics products
The FDA has granted market clearance for CardioDynamics’ BioZ impedance cardiography (ICG) clinical parameters and 510(k) clearance for its expanded BioZ Dx system EMR interface capability.

The BioZ Dx was produced out of a co-development partnership between the CardioDynamics and Philips Medical Systems.

The new ICG clinical parameters include total arterial compliance and Q-C time interval, according to the San Diego-based CardioDynamics.